Table 6.
Discordance of the expression status of the biomarkers between breast PTs and synchronous ALN metastases.
| Biomarker | Discordance rate (%) | ALN metastases | |
|---|---|---|---|
| Loss of expression relative to the paired PT (+) -> (-) | Gain of expression relative to the paired PT (-) -> (+) | ||
| Ki-67 | 10/43 (23.2) | 5 | 5 |
| ER | 8/47 (17) | 3 | 5 |
| PR | 8/44 (18.2) | 2 | 6 |
| HER2 | 0/49 | – | |
| E-cadherin | 12/23 (52.2) | 12 | – |
| Cyclin D1 | 9/44 (20.5) | 3 | 6 |
| Bcl-2 | 11/42 (26.2) | 4 | 7 |
| GCDFP-15 (35) | 15/50 (30) | 8 | 7 |
| PD-L1 | 5/22 (22.7) | 3 | 2 |
| Snail+Slug | 1/21 (4.8) | – | 1 |
| PRL-3 (36) | 8/21 (38.1) | 5 | 3 |
It demonstrates how many paired samples showed the difference in the expression of the marker, i.e., how many ALN tumors gained or lost the expression of the marker relative to the paired PT sample.
ALN, axillary lymph node; ER, estrogen receptor; PR, progesterone receptor; PT, primary tumor.